Physician profile
Claude Steriade
NPI 1013369446
$52,254.46
in general payments reported to CMS, 2019-2025
9 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,770 · 2023: $13K · 2024: $17K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Honoraria: $3,850 · Food and Beverage: $1,137 · Travel and Lodging: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,995.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,036.00 |
| Honoraria | $3,850.00 |
| Food and Beverage | $1,136.58 |
| Travel and Lodging | $466.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $20,151.94 | 2024-2025 | Valtoco |
| Ucb Sa | $11,095.00 | 2022-2023 | |
| Ucb, INC. | $10,625.00 | 2024-2025 | |
| Sk Life Science, INC. | $4,000.58 | 2024-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $3,900.00 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $2,481.94 | 2023-2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Steriade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.